← Drug database

Avamys (fluticasone furoate)

Region
🇪🇺 EU
Active substance
fluticasone furoate
Company
GlaxoSmithKline Trading Services Limited
Status
Authorised
Therapeutic area
Rhinitis, Allergic, Seasonal; Rhinitis, Allergic, Perennial
EU approval
Fri 11 Jan 2008
Application
EMEA/H/C/000770
ATC
R01AD12
Official record
www.ema.europa.eu

Indication

Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated for the treatment of the symptoms of allergic rhinitis.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Avamys

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.